Retatrutide monograph

Retatrutide

Overview

Retatrutide is an investigational, once-weekly injectable incretin-based peptide that activates GLP-1, GIP, and glucagon receptors. In phase 2 studies, it produced large dose-dependent reductions in body weight and HbA1c, with cardiometabolic improvements, but it is not FDA-approved. It is not a bodybuilding drug in the evidence-based sense; the appeal is fat loss, but the risk profile is the same GI-heavy GLP-1 class plus added uncertainty because the human dataset is still developing. Weight loss still comes primarily from eating less — the same liraglutide-class rule — and if protein intake and resistance training are not protected, lean mass can fall with the fat.

Pharmacokinetics & Mechanism

• Class: Investigational long-acting triple agonist peptide (GLP-1/GIP/glucagon receptor agonist)
• Mechanism of action: Retatrutide is a synthetic peptide that acts as a triple agonist at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. The combined incretin and glucagon signaling is intended to reduce appetite and energy intake, improve glycemic control, and increase energy expenditure, which together drive weight loss. Human mechanistic and outcomes data are still emerging, so the full downstream effects beyond weight and HbA1c reduction are not yet firmly established.
• Target(s): GIP receptor; GLP-1 receptor; glucagon receptor. Downstream pathways include appetite/satiety signaling, insulin secretion, glucagon modulation, and energy expenditure pathways.
• Route(s) of administration: Subcutaneous injection only in clinical studies; once weekly.
• Onset: Not well established in humans. Clinically, appetite suppression and reduced intake are typically expected within the first dose-escalation weeks, but the precise onset for retatrutide has not been established in a way that can be generalized.
• Half-life: Not well established in the publicly accessible sources reviewed here. The clinical program uses once-weekly dosing, which implies a long apparent half-life, but I did not find a reliable human half-life value to quote from the sources accessed.
• Metabolism / clearance: Not well established in humans. As a peptide, it is expected to undergo proteolytic degradation to amino acids and peptide fragments with systemic clearance rather than CYP-mediated metabolism, but a definitive human clearance description was not established in the sources reviewed.